These findings suggest that TC-I 15 inhibits OSCC and enhances the sensitivity of OSCC to chemotherapy, highlighting the potential of targeting ITGA2 to improve clinical anti-tumor efficacy. This evidence concerns the gene ITGA2 and neoplasm.